Resources
182 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/25/2022 (updated 4/26/2024)
A guidebook from the Substance Abuse and Mental Health Services Administration describes various methods of adapting evidence-based practices for substance use disorder (SUD) to meet the needs of populations who experience barriers in receiving behavioral health services due to a variety of factors including race, ethnicity, geography, income, sexual orientation, and disability.
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 2/14/2023 (updated 4/15/2024)
The RCORP Data Coordinator meeting series began in July 2022, hosted by RCORP-Evaluation in partnership with RCORP-TA. These meetings provide an opportunity for the JBS RCORP team to work with Data Coordinators and other consortium staff to address topics impacting data quality, reporting and utilization. Discussion in these meetings helps to inform additional webinar sessions and resources, developed to meet grantee needs.
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 5/17/2021 (updated 4/10/2024)
This webinar will present the OUD Cascade of Care, explain how to create one for your program and use it to evaluate and sustain your MOUD continuum of care.
Learning Objectives:
Understand the cascade of care for opioid use disorder (OUD)
Define metrics for your OUD cascade of care
Use the cascade of care to take action that improves sustainability
Target Audience: Implementation I, Implementation II, MAT Expansion, but all cohorts are welcome
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 5/12/2021 (updated 4/10/2024)
64,000 people died from an overdose in the U.S. in 2016. Fentanyl-related deaths are up 540% in the last 3 years. In 2016 72% of the 1,374 fatal overdoses in NYC involved heroin and/or fentanyl